14-day Premium Trial Subscription Try For FreeTry Free

Unicycive Therapeutics, Inc. Stock Insider Power

Based on the 65 latest insides trades, we have calculated the insider power to be positive at 90.36. In total, the insiders bought 72 706 618 and sold 8 197 UNCY shares in the last 65 trades.

Insider Power

(Last 65 transactions)
90.36
Buy 72 706 618 Shares
Sell 8 197 Shares

Historical Insider Trades

Date Type Action Person Amount
Apr 15, 2024 Stock Options Buy Townsend John 228 119
Apr 15, 2024 Stock Options Buy Jermasek Douglas 463 250
Apr 15, 2024 Stock Options Buy Gupta Pramod 463 250
Apr 15, 2024 Stock Options Buy Gupta Shalabh K. 1 319 583
Sep 05, 2023 Stock Options Buy Laumas Sandeep 189 236
Sep 05, 2023 Stock Options Buy Kenkare-mitra Sara 180 000
Sep 05, 2023 Stock Options Buy Ryan John L 112 147
Sep 05, 2023 Stock Options Buy Aggarwal Gaurav 180 000
Sep 05, 2023 Buy Kenkare-mitra Sara 0
Aug 28, 2023 Stock Options Buy Gupta Pramod 1 355 000
Aug 28, 2023 Stock Options Buy Gupta Shalabh K. 4 684 775
Aug 28, 2023 Stock Options Buy Townsend John 570 329
Aug 28, 2023 Stock Options Buy Jermasek Douglas 1 355 000
Jul 11, 2023 Tranche C Warrants (right to buy) Buy Aggarwal Gaurav 18 621 655
Jul 11, 2023 Series A-2 Preferred Stock Buy Aggarwal Gaurav 13 429 000
Jul 11, 2023 Tranche A Warrants (right to buy) Buy Aggarwal Gaurav 12 802 388
Jul 11, 2023 Tranche B Warrants (right to buy) Buy Aggarwal Gaurav 11 638 534
Jul 11, 2023 Common Stock Buy Aggarwal Gaurav 3 470 152
Jul 11, 2023 Series A-1 Preferred Stock Sell Aggarwal Gaurav 8 077
Jul 11, 2023 Common Stock Buy Jermasek Douglas 104 612
Jul 11, 2023 Warrant (right to buy) Buy Jermasek Douglas 115 275
Jul 11, 2023 Warrant (right to buy Buy Jermasek Douglas 79 252
Jul 11, 2023 Warrant (right to buy) Buy Jermasek Douglas 72 047
Jul 11, 2023 Series A-1 Convertible Preferred Stock Sell Jermasek Douglas 50
Jul 11, 2023 Warrant (right to buy) Buy Gupta Pramod 46 110
Click to get the best stock tips daily for free!

About Unicycive Therapeutics, Inc.

Unicycive Therapeutics. Unicycive Therapeutics, Inc., a biotechnology company, engages in developing novel therapies for kidney diseases in the United States. It is developing Renazorb for treatment of hyperphosphatemia in patients with chronic kidney disease; and UNI 494, for treatment of acute kidney injury. The company was incorporated in 2016 and is based in Los Altos, California.... UNCY Profile

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE

ROCKIT